ADVERTISEMENT
Search

Prescribing Considerations for COVID-19 Therapeutics

Prescribing Considerations for COVID-19 Therapeutics

This program, supported by Pfizer, was developed to support pharmacists' awareness and understanding of potentially significant drug interactions and contraindicated drugs with COVID-19 Therapeutics (DDI).

The program includes the following educational activities:

Prescribing Considerations for COVID-19 Therapeutics

This one-hour interactive, application-based case-study CE course provides information about patient identification for use of COVID-19 therapeutics in patients with mild to moderate COVID-19 and risk factors for progression to severe COVID-19. You’ll navigate patient identification for treatment, managing drug-drug interactions, and when to refer patients to their primary care provider for additional follow-up.

Access Now 

Show You Know: Assess Patients for Appropriate COVID-19 Therapeutics

Pharmacists have been pivotal in the fight against COVID-19. Under the PREP Act, pharmacy technicians, pharmacy interns, and pharmacists have been immunizing community members and dispensing COVID-19 therapeutics. Most recently, pharmacists have been given the authority to prescribe one COVID-19 oral therapeutic. Test your knowledge with this short quiz!

Access Now 

Pharmacists Prescribing COVID-19 Therapeutics

There is no one better than the pharmacist to assess and intervene when potentially serious drug-drug interactions occur. For the first time ever, pharmacists can prescribe! So now what? This 2-part series of podcasts, hosted by Dr. Randy McDonough, features pharmacists who are currently prescribing Paxlovid. They discuss their experience helping a patient manage drug-drug interactions so that Paxlovid could be prescribed safely and considerations for preparing and implementing prescribing services in the pharmacy.

Access Now 

Focus On: Pharmacists Prescribing COVID-19 Therapeutics

This resource is designed to offer pharmacists a concise and accurate tool for assessing patient eligibility for pharmacist-prescribed nirmatrelvir/ritonavir, including identifying and managing drug interactions. Pearls for implementing this clinical service are also provided. This guide is meant to build on the infrastructure and practices community pharmacists are already employing to contend with COVID-19 and incorporate this new authority to further benefit the public.